In an animal cachexia model, treatment with BPC157 (body protection compound 157) with TNF-α antagonists, such as infliximab or adalimumab, not only improved cachexia but also improved the prognosis of cancer.[32] Subramaniam et al[6] reported that infliximab reverses inflammatory sarcopenia in CD, and Dos Santos et al[33] reported that all components of body composition improved after therapy with infliximab. This evidence concerns the gene TNF and Cachexia.